Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, QT interval and dispersion in patients with gastrointestinal system cancers

Japanese Journal of Clinical Oncology

Volumn 34, Issue 5, 2004, Pages 262-268

  Oztop, Ilhan ^a   Gencer, Murat ^a   Okan, Taha ^a   Yaren, Arzu ^a   Altekin, Emel ^a   Turker, Sonay ^a   Yilmaz, Ugur ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; Cardiotoxicity; Echocardiography; QT dispersion; Troponin I

Indexed keywords

FLUOROURACIL; FOLINIC ACID; TROPONIN I; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BOLUS INJECTION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLORECTAL CANCER; DIASTOLE; DIGESTIVE SYSTEM CANCER; DRUG INFUSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PROTEIN BLOOD LEVEL; QT DISPERSION; QT INTERVAL; STOMACH CANCER; SYSTOLE; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; ECHOGRAPHY; ELECTROCARDIOGRAPHY; GASTROINTESTINAL TUMOR; HEART; PATHOPHYSIOLOGY; PROSPECTIVE STUDY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HEART; HUMANS; LEUCOVORIN; MALE; PROSPECTIVE STUDIES; TROPONIN I;

EID: 3342887068     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh047     Document Type: Article

References (56)

1. De Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L, et al. Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical study. J Clin Oncol 1992;10:1795-801.
2. Akhtar S, Salim K, Bano Z. Symptomatic cardiotoxicity with high-dose 5-fluorouracil infusion: A prospective study. Oncology 1993;50:441-4.
3. Meyer C, Anton Calis K, Burke L, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy 1997;17:729-36.
4. Labianca R, Beretta G, Clerici M, Fraschini P, Luporini G. Cardiac toxicity of 5-fluorouracil: A study on 1083 patients. Tumori 1982;68:505-10.
5. Schober C, Papageorgiou E, Harstrick A, Bokemeyer C, Mugge A, Stahl M, et al. Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. Cancer 1993;72:2242-7.
6. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, et al. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 2002;8:151-7.
7. Grandi AM, Pinotti G, Morandi E, Zanzi P, Bulgheroni P, Guasti L, et al. Noninvasive evaluation of cardiotoxicity of 5-fluorouracil and low doses of folinic acid: A one-year follow-up study. Ann Oncol 1997;8:705-8.
8. Carrio I, Estorch M, Berna L, Germa JR, Alonso C, Ojeda B, et al. Assessment of anthracycline-induced myocardial damage by quantitative indium-111 myosin-specific monoclonal antibody studies. Eur J Nucl Med 1991;18:806-12.
9. Yamada T, Matsumori A, Tamaki N, Morishima S, Watanabe Y, Yonekura Y, et al. Detection of adriamycin cardiotoxicity with indium-111 labeled antimyosin monoclonal antibody imaging. Jpn Circ J 1991;55:377-83.
10. Viniegra M, Marchetti M, Losso M, Navigante A, Litovska S, Senderowicz A, et al. Cardiovascular autonomic function in anthracycline-treated breast cancer patients. Cancer Chemother Pharmacol 1990;23: 227-31.
11. Billingham ME, Bristow MR. Evaluation of anthracycline cardiotoxicity: predictive ability and functional correlation of endomyocardial biopsy. Cancer Treat Symp 1984;3:71-6.
12. Chapelle JP. Cardiac troponin I and troponin T: Recent players in the field of myocardial markers. Clin Chem Lab Med 1999;37:11-20.
13. Stubbs P. The cardiac troponins uses in routine clinical practice. Experience from GUSTO and other clinical trials. Eur Heart J 1998;19(Suppl N):N59-63.
14. Stromme JH, Johansen O, Brekke M, Seljeflot I, Amesen H. Markers of myocardial injury in blood following PTCA: A comparison of CKMB, cardiospecific troponin T and troponin I. Scand J Clin Lab Invest 1998; 58:693-9.
15. La Vecchia L, Mezzena G, Ometto R, Finocchi G, Bedogni F, Soffiati G, Vincenzi M. Detectable serum troponin I in patients with heart failure of non myocardial ischemic origin. Am J Cardiol 1997;80:482-5.
16. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, Schultheiss HP. Cardiac troponin T in patients with clinically suspected myocarditis. J Am Coll Cardiol 1997;30:1354-9.
17. 2) cyclophosphamide. Bone Marrow Transplant 2001;28:277-82.
18. Elming H, Holm E, Jun L, Torp-Pedersen C, Kober L, Kircshoff M, et al. The prognostic value of the QT interval and QT interval dispersion in all-cause and cardiac mortality and morbidity in a population of Danish citizens. Eur Heart J 1998;19:1391-400.
19. Veglio M, Giunti S, Stevens LK, Fuller JH, Perin PC, The EURODIAB IDDM Complications Study Group. Prevelance of QT interval dispersion in type I diabetes and its relation with cardiac ischemia. Diabetes Care 2002;25:702-7.
20. Naas AAO, Davidson NC, Thompson C, Cummings F, Ogston SA, Jung RT, et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin-dependent diabetes: A cohort study. Br Med J 1998;316:745-6.
21. Sawicki PT, Kiwitt S, Bender M, Berger M. The value of QT interval dispersion for identification of total mortality risk in non-insulin-dependent diabetes mellitus. J Intern Med 1998;243:49-56.
22. Van de Loo A, Arendts W, Hohnloser SH. Variability of QT dispersion measurements in the surface electrocardiogram in patients with acute myocardial infarction and in normal subjects. Am J Cardiol 1994;74: 1113-8.
23. Bazett HC. An analysis of time-relations of electrocardiograms. Hearts 1920;7:353-70.
24. Sahn JD, DeMaria A, Kisslo J, Weyman A. The committee on M-mode Standardization of the American Society of Echocardiography. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58: 1072-83.
25. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, Ottlinger ME. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-8.
26. Auner HW, Tinchon C, Linkesch W, Tiran A, Quehenberger F, Link H, Sill H. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann Hematol 2003;82:218-22.
27. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997;8:537-41.
28. Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002;13:710-5.
29. Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem 2003;49: 248-52.
30. Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000;36:517-22.
31. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Progr Cardiovasc Dis 2001;43(Suppl):1-45.
32. Sawicki PT, Dahne R, Bender R, Berger M. Prolonged QT interval as a predictor of mortality in diabetic nephropathy. Diabetologia 1996;39:77-81.
33. Veglio M, Sivieri R, Chinaglia A, Scaglione L, Cavallo-Perin P. QT interval prolongation and mortality in type I diabetic patients. Diabetes Care 2000;23:1381-3.
34. Rossing P, Breum L, Major-Pederesen A, Sato A, Winding H, Pietersen A, et al. Prolonged QTc interval predicts mortality in patients with type I diabetes mellitus. Diabet Med 2001;18:199-205.
35. Cowan JC, Hilton CJ, Griffiths CJ. Sequence of epicardial repolarization and configuration of the T wave. Br Heart J 1988;60:424-33.
36. Sylven JC, Horacek BM, Spencer CA, Klassen GA, Montague TJ. QT interval variability on the body surface. J Electrocardiol 1994;17:179-88.
37. Kautzner J, Malik M. QT interval dispersion and its clinical utility. PACE 1997;20:2625-40.
38. Kautzner J. QT interval measurements. Cardiac Electrophysiol Rev 2002; 6:273-7.
39. Day CP, MeComb JM, Cambell RW. QT dispersion: An indication of arrhythmic risk in patients with long QT intervals. Br Heart J 1990;63: 342-4.
40. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9.
41. Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993;72:973-6.
42. Zareba W, Moss AJ, Le Cessie S. Dispersion of ventricular repolarization and arrhythmic cardiac death in coronary artery disease. Am J Cardiol 1994;74:550-3.
43. Pye M, Quinn AC, Cobbe SM. QT interval dispersion: A non-invasive marker of susceptibility to arrhythmia in patients with sustained ventricular arrhythmias? Br Heart J 1994;71:511-4.
44. Campbell RW, Furniss SS. Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. Am J Cardiol 1993; 72:80A-85A.
45. Hii JT, Wyse DG, Gillis AM, Duff HJ, Solylo MA, Mitchell LB. Precordial QT interval dispersion as a marker of torsades de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone. Circulation 1992; 86:1376-82.
46. Malik M, Batchvarov VN. Clinical potential of QT dispersion. J Am Coll Cardiol 2000;36:1749-66.
47. Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet 2000;355:805-6.
48. Bender KS, Shematek JP, Leventhal BG, Kan JS. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 1984;105:442-4.
49. Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993;11:1906-10.
50. Ferrari S, Figus E, Cagnano R, Iantorno D, Bacci G. The role of corrected QT interval in the cardiologic follow-up of young patients treated with adriamycin. J Chemother 1996;8:232-6.
51. Nousiainen T, Vanninen E, Rantala A, Jantunen E, Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Int Med 1999;245:359-64.
52. Keefe DL. The cardiotoxic potential of the 5-HT3 receptor antagonist antiemetics: Is there cause for concern? Oncologist 2002;7:65-72.
53. Jantunen IT, Kataja VV, Muhonen TT, Parviainen T. Effects of granisetron with doxorubicin or epirubicin on ECG intervals. Cancer Chemother Pharmacol 1996;5:502-4.
54. Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine 3 receptor antagonists. Ann Pharmacother 2003;9:1276-86.
55. Carmichael J, Philip PA, Forfar C, Harris AL. An open study to assess the safety, tolerance and pharmacokinetics of an intravenous infusion of granisetron given at 3 mg over 30 s in patients receiving chemotherapy for malignant disease. Cancer Chemother Pharmacol 1995;37:134-8.
56. Aapro M, Bourke JP. Rapid intravenous administration of granisetron prior to chemotherapy is not arythmogenic: Results of a pilot study. Eur J Cancer 2003;39:927-31.